دورية أكاديمية

SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials

التفاصيل البيبلوغرافية
العنوان: SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
المؤلفون: Conte B., Boni L., Bisagni G., Durando A., Sanna G., Gori S., Garrone O., Tamberi S., De Placido S., Schettini F., Pazzola A., Ponzone R., Montemurro F., Lunardi G., Notaro R., De Angioletti M., Turletti A., Mansutti M., Puglisi F., Frassoldati A., Porpiglia M., Fabi A., Generali D., Scognamiglio G., Rossi M., Braso-Maristany F., Prat A., Cardinali B., Piccioli P., Serra M., Lastraioli S., Bighin C., Poggio F., Lambertini M., Del Mastro L.
المساهمون: Conte, B., Boni, L., Bisagni, G., Durando, A., Sanna, G., Gori, S., Garrone, O., Tamberi, S., De Placido, S., Schettini, F., Pazzola, A., Ponzone, R., Montemurro, F., Lunardi, G., Notaro, R., De Angioletti, M., Turletti, A., Mansutti, M., Puglisi, F., Frassoldati, A., Porpiglia, M., Fabi, A., Generali, D., Scognamiglio, G., Rossi, M., Braso-Maristany, F., Prat, A., Cardinali, B., Piccioli, P., Serra, M., Lastraioli, S., Bighin, C., Poggio, F., Lambertini, M., Del Mastro, L.
سنة النشر: 2023
المجموعة: Università degli Studi di Udine: CINECA IRIS
الوصف: Purpose: In estrogen receptor–positive (ERþ) breast cancer, single-nucleotide polymorphisms (SNP) in the aromatase gene might affect aromatase inhibitors (AI) metabolism and efficacy. Here, we assessed the impact of SNP on prognosis and toxicity of patients receiving adjuvant letrozole. Experimental Design: We enrolled 886 postmenopausal patients in the study. They were treated with letrozole for 2 to 5 years after taking tamoxifen for 2 to 6 years, continuing until they completed 5 to 10 years of therapy. Germline DNA was genotyped for SNP rs4646, rs10046, rs749292, and rs727479. Log-rank test and Cox model were used for disease-free survival (DFS) and overall survival (OS). Cumulative incidence (CI) of breast cancer metastasis was assessed through competing risk analysis, with contralateral breast cancer, second malignancies and non-breast cancer death as competing events. CI of skeletal and cardiovascular events were assessed using DFS events as competing events. Subdistribution HR (sHR) with 95% confidence intervals were calculated through Fine-Gray method. Results: No SNP was associated with DFS. Variants rs10046 [sHR 2.03, (1.04–2.94)], rs749292 [sHR 2.11, (1.12–3.94)], and rs727479 [sHR 2.62, (1.17–5.83)] were associated with breast cancer metastasis. Three groups were identified on the basis of the number of these variants (0, 1, >1). Variant-based groups were associated with breast cancer metastasis (10-year CI 2.5%, 7.6%, 10.7%, P 1⁄4 0.035) and OS (10-year estimates 96.5%, 93.0%, 89.6%, P 1⁄4 0.030). Co-occurrence of rs10046 and rs749292 was negatively associated with 10-year CI of skeletal events (3.2% vs. 10%, P 1⁄4 0.033). A similar association emerged between rs727479 and cardiovascular events (0.3% vs. 2.1%, P 1⁄4 0.026). Conclusions: SNP of aromatase gene predict risk of metastasis and AI-related toxicity in ERþ early breast cancer, opening an opportunity for better treatment individualization.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: volume:29; issue:24; firstpage:5217; lastpage:5226; numberofpages:10; journal:CLINICAL CANCER RESEARCH; https://hdl.handle.net/11390/1270549Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85180010688
DOI: 10.1158/1078-0432.CCR-23-1568
الإتاحة: https://doi.org/10.1158/1078-0432.CCR-23-1568Test
https://hdl.handle.net/11390/1270549Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.57EB1378
قاعدة البيانات: BASE